Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
via Samsara BioCapital, LLC, Siren, L.L.C., Marshall Wace LLP · 71.42% of KLRS, 22.74% of RANI
via Samsara BioCapital, LLC, Siren, L.L.C., Marshall Wace LLP +1 more · 71.42% of KLRS, 18.57% of VTVT
via Samsara BioCapital, LLC, RTW Investments, LLC, Woodline Partners LP · 71.42% of KLRS, 9.84% of NGNE
via Samsara BioCapital, LLC, Ikarian Capital, LLC, Alyeska Investment Group, L.P. +4 more · 71.42% of KLRS, 7.47% of IVA
via Samsara BioCapital, LLC, Woodline Partners LP, Alyeska Investment Group, L.P. · 71.42% of KLRS, 10.17% of ALMR
via RTW Investments, LLC, Samsara BioCapital, LLC, Marshall Wace LLP · 7.21% of KLRS, 10.08% of AQST
Managers holding a meaningful stake in KLRS also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.
56 institutional managers report a position in Kalaris Therapeutics, Inc. worth $73.4M between them, filed on form 13F for the quarter ending 2026-06-30. 3 of them hold 80% of it, the largest being Samsara BioCapital, LLC at 71.42%.
31 more managers in the register
3 managers hold 80% of the $73.4M institutional base. The other 53 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
Kalaris Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 3.22 · gapped above the open, never looked back. High/low 3.36 at 12:30 pm ET, 3.22 at 3:45 pm ET.
KLRS (Kalaris Therapeutics, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.